Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes, Type 2

In brief

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Key facts

Study ID

NCT01336738

Run by

Pfizer

People needed

266

Starts

2011-06-01

Expected to finish

2012-03-01

Last updated by the study team

2013-08-06

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with type 2 diabetes on stable doses of background medicines for management of diabetes; aged 18-70 years; body mass index between 22.5 and 45.5 kg/m2

You may not qualify if…

• Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease.

Where it is running

• Pfizer Investigational Site — Jonesboro, Arkansas, United States
• Pfizer Investigational Site — Jonesboro, Arkansas, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Palm Springs, California, United States
• Pfizer Investigational Site — Jacksonville, Florida, United States
• Pfizer Investigational Site — Melbourne, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Conyers, Georgia, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Fall River, Massachusetts, United States
• Pfizer Investigational Site — Brooklyn, New York, United States
• Pfizer Investigational Site — Cary, North Carolina, United States
• Pfizer Investigational Site — Wilmington, North Carolina, United States
• Pfizer Investigational Site — Columbus, Ohio, United States
• Pfizer Investigational Site — East Providence, Rhode Island, United States
• Pfizer Investigational Site — East Providence, Rhode Island, United States
• Pfizer Investigational Site — Mt. Pleasant, South Carolina, United States
• Pfizer Investigational Site — Bristol, Tennessee, United States
• Pfizer Investigational Site — Kingsport, Tennessee, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.